<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574324</url>
  </required_header>
  <id_info>
    <org_study_id>20180602</org_study_id>
    <nct_id>NCT03574324</nct_id>
  </id_info>
  <brief_title>TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC</brief_title>
  <official_title>A Multicenter, Randomized Controlled Phase III Clinical Trial of TPF Induction Chemotherapy Versus PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guiyang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guiyang Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through randomized controlled phase III multicenter clinical trials, TPF induction
      chemotherapy vs. PF regimen adjuvant chemotherapy concurrently Radiotherapy and chemotherapy
      for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and
      quality of life, and further improvement Survival rate and improve the quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Anticipated">May 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progress-free survival(year) is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The OS(year) was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The LRFS(year) is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The DMFS(year) is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 weeks after completion of concurrent chemoradiotherapy</time_frame>
    <description>Tumour response(CR/PR/SD/PD) was classified according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of acute toxicity（Grade1/2/3/4） is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Locally Advanced Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRE+PF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF+CCRT</intervention_name>
    <description>Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy</description>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <other_name>Experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCRT+PF</intervention_name>
    <description>Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles</description>
    <arm_group_label>CCRE+PF</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing (according to World
             Health Organization (WHO) histologically type).

          2. Clinical staged as III，IVa（according to the American Joint Committee on Cancer(AJCC)
             7th edition）

          3. Fertility women should ensure contraception during entry into the study.

          4. Age 18-69 years old.

          5. Karnofsky scale(KPS)≥70.

          6. Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count
             ≥100000/μL.

          7. Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤ULN.

          8. Adequate renal function: creatinine clearance ≥60 ml/min.

          9. Patients must be informed of the investigational nature of this study and give written
             informed consent

        Exclusion Criteria:

          1. With distant metastasis.

          2. who had received prior chemotherapy or radiotherapy.

          3. patients have physical or mental illness, and by researchers believe that patients
             4.can not be completely or fully understood in this study possible complications.

        5.pregnancy (via the urine or serum β-HCG test confirmed) or during lactation. 6.serious
        complications, such as uncontrolled hypertension, heart failure, diabetes and so on.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuanyuan Li, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guizhou Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Jin, Bachelor</last_name>
    <phone>0851-86512802</phone>
    <email>jinf8865@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyuan Li, Master</last_name>
    <phone>0851-86512802</phone>
    <email>lilyuanyuan@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>贵州省</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanyuan Li, master</last_name>
      <phone>085186512802</phone>
      <email>lilyuanyuan@qq.com</email>
    </contact>
    <investigator>
      <last_name>Feng Jin, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weili Wu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhua Long, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuling Luo, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuyun Gong, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hang Jiang, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanfang Cen, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guiyang Medical University</investigator_affiliation>
    <investigator_full_name>Feng Jing</investigator_full_name>
    <investigator_title>Head and neck cancer director, chief researcher, clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

